Inogen Stock News

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.

Inogen <> expects FY2021 revenue in the range of $357.5M to $358.5M, up 15.9% to 16.2% Y/Y vs

Brokerages expect Inogen, Inc. (NASDAQ:INGN) to post ($0.77) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Inogens earnings. The lowest EPS estimate is ($0.82) and the highest is ($0.73). Inogen posted earnings per share of ($0.23) during the same quarter last year, which would suggest a []

Profiles of major market players operating in the medical oxygen cylinder market, which include Drive DeVilbiss Healthcare, Inc., Philips Healthcare, Invacare Corporation, Nidek Medical, Inogen, Inc., AirSep Corporation, ResMed, Medical Depot, Inc., CAIRE Inc., O2 CONCEPTS, OxyGo, LLC, Precision Medical, Inc., Linde plc, CDMI Profiles of major market players operating in the medical oxygen cylinder market, which include Drive DeVilbiss Healthcare, Inc., Philips Healthcare, Invacare Corporation, Nidek Medical, Inogen, Inc., AirSep Corporation, ResMed, Medical Depot, Inc., CAIRE Inc., O2 CONCEPTS, OxyGo, LLC, Precision Medical, Inc., Linde plc, CDMI

Analysts forecast that Inogen, Inc. (NASDAQ:INGN) will post sales of $74.61 million for the current quarter, Zacks reports. Five analysts have provided estimates for Inogens earnings, with the lowest sales estimate coming in at $74.00 million and the highest estimate coming in at $76.00 million. Inogen reported sales of $73.98 million during the same quarter []

Inogen and Eargo are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability

Inogen (NASDAQ:INGN) and Eargo (NASDAQ:EAR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of recent recommendations and price targets for Inogen and Eargo, as [] The post Comparing Inogen (NASDAQ:INGN) & Eargo (NASDAQ:EAR) appeared first on ETF Daily News .

Inogen, Inc. (NASDAQ:INGN) has been assigned an average recommendation of Hold from the eight brokerages that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have []

Brokerages expect Inogen, Inc. (NASDAQ:INGN) to report $75.35 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Inogens earnings, with estimates ranging from $74.00 million to $77.80 million. Inogen posted sales of $73.98 million during the same quarter last year, which would suggest a positive year-over-year growth rate []

Comerica Bank cut its stake in Inogen, Inc. (NASDAQ:INGN) by 6.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,365 shares of the medical technology companys stock after selling 1,285 shares during the quarter. Comerica Banks holdings in Inogen were worth []

Key Players covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, US), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, US), Amgen Inc. (California, US), Mylan N.V. (Pennsylvania, US), Coherus BioSciences (California, US), Other Prominent Players Key Players covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, US), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, US), Amgen Inc. (California, US), Mylan N.V. (Pennsylvania, US), Coherus BioSciences (California, US), Other Prominent Players

Invesco Ltd. lifted its stake in shares of Inogen, Inc. (NASDAQ:INGN) by 1.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 112,135 shares of the medical technology companys stock after buying an additional 1,923 shares during the quarter. Invesco Ltd. owned about 0.50% []